The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | XPO1 inhibition with selinexor for RRMM
Lisa Leypoldt, MD, University Medical Center Hamburg, Hamburg, Germany, discusses XPO1 inhibition with selinexor for the treatment of relapsed/refractory multiple myeloma (RRMM). This drug is approved in this setting in combination with bortezomib and dexamethasone based on the STORM (NCT02336815) and the BOSTON (NCT03110562) trials. It is a potential option for patients who are triple-class refractory or for bridging to CAR-T therapy. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
